A total of 10 305 participants were randomised to the LLA, which was prematurely stopped in September 2002 at the recommendation of the Data Safety and Monitoring Board due to a highly significant reduction in the primary end point, along with reductions in several other CV end points in favour of atorvastatin. 1 At the end of the trial, all participants were offered atorvastatin 10 mg.
← all excerpts
Long-term benefits of atorvastatin on the incidence of cardiovascular events: the ASCOT-Legacy 20-year follow-up.
1
—
—